Chromosomal instability can result from defective control of checkpoints and is associated with malignant cell growth. Monopolar spindle 1 (Mps1) is a dualspecificity protein kinase that has important roles in the prevention of aneuploidy during the cell cycle, and might therefore be a potential target for new therapeutic agents in the treatment of cancer. To gain insights into the molecular mechanism of Mps1 inhibition by small molecules, we determined the X-ray structure of Mps1, both alone and in complex with the ATPcompetitive inhibitor SP600125. Mps1 adopts a classic protein kinase fold, with the inhibitor sitting in the ATP-binding site where it is stabilized by hydrophobic interactions. We identified a secondary pocket, not utilised by SP600125, which might be exploited for the rational design of specific Mps1 inhibitors. These structures provide important insights into the interaction of this protein kinase with small molecules and suggest potential mechanisms for Mps1 regulation.
Introduction
The human protein kinase Mps1, also known as TTK, is an evolutionary conserved regulator of chromosome stability in eukaryotes (1, 2) . Mps1 is important for the duplication of centrosomes (3), the spindle assembly checkpoint (4) , and accurate chromosome alignment during mitosis (5) , and several cellular Mps1 substrates that support these functional roles have recently been described (5-7). Mps1 consists of an Nterminal non-catalytic region and a C-terminal catalytic domain, which exhibits weak sequence homology with other human kinases, but is more highly conserved amongst eukaryotic Mps1 orthologues (2) . Mps1 exhibits dual-specificity kinase activity in vitro, which is controlled by reversible autophosphorylation of at least one residue in the activation segment (8, 9) . The non-specific compound SP600125 was first characterized as an inhibitor of c-Jun N-terminal Kinase (JNK) activity in human cells (10) and the co-crystal structure of the closely related kinases JNK1 and JNK3 in complex with SP600125 have been reported (11, 12) . SP600125 induces mitotic phenotypes in human cells consistent with Mps1 inhibition (5, 13) , and drugresistant Mps1 mutants have been employed to show that Mps1 is the probable target of SP600125 responsible for some of these effects (13) . In a similar vein, the Mps1-dependent spindle assembly checkpoint is blocked in budding yeast by the action of the compound cincreasin, which rapidly generates non-viable cells (14) .
Given its importance during mitosis, potent Mps1 inhibitors might represent novel therapeutic agents in proliferative disorders (15) . However, the design of specific inhibitors has been hampered by the lack of an available structure of the Mps1 catalytic domain. In order to gain further insights into the mechanism of inhibition of Mps1 by ATPcompetitive inhibitors, and to aid the development of selective compounds, we have determined the crystal structure of the unphosphorylated form of Mps1 catalytic domain, both alone (apo-kinase) and in complex with SP600125.
The catalytic domain of Mps1 adopts the classical fold of protein kinases, with the activation loop packing against the N-terminal lobe, where it induces conformational changes indicative of an inactive form of the enzyme. The structure of the complex with SP600125 shows the inhibitor bound in the ATP-binding site and highlights distinct structural features in the active site cleft that can be exploited for rational drug design.
Experimental Procedures
Cloning, expression, purification and crystallisation of Mps1. DNA encoding residues 510 -857 of human Mps1 (SP entry P33981) was amplified by PCR and cloned into the vector pET-30 EK/LIC (Novagen). The point mutants D664A and T686A were created by PCR with the wild-type (WT) template using standard mutagenic procedures. Recombinant His-tagged proteins were expressed in E. coli BL21 (DE3) pLysS cells (Novagen). Cells were harvested and then lysed by sonication into buffer A (50 mM TrisHCl (pH 7.4 at 4°C), 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 20 mM imidazole, 0.1 % Triton X-100, 2 mM dithiothreitol (DTT), 0.1 mM benzamidine, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and an EDTA-free protease inhibitor cocktail (Roche). Proteins were purified by affinity chromatography over Ni-NTA His•Bind resin (Novagen) and eluted in an imidazole gradient in buffer A, followed by size-exclusion chromatography through Superdex 200 (GE Healthcare) in buffer B (50 mM Tris-HCl (pH 7.4 at 4°C), 150 mM NaCl, 0.1 mM EGTA, 2 mM DTT, 0.1 mM benzamidine, 0.2 mM PMSF) and ion-exchange chromatography on a Mono Q column (GE Healthcare), from which proteins were eluted with a NaCl gradient (0-1 M) in 10 mM Tris (pH 8.0 at 4°C). Prior to crystallization, WT Mps1 was treated with λ-phosphatase (NEB) overnight at room temperature, to permit dephosphorylation of the kinase, and repurified through a Mono Q column. The purified samples were concentrated to 5 mg. (16) with the coordinates of phosphorylase kinase (Phk) as a search model (PDB ID 1phk). This identified one molecule of WT apo-Mps1 per asymmetric unit, with interpretable electron density for residues Glu516 -Met671, Asp681 -Met698 and Ser709 -Gln794. The structure of Mps1 T686A mutant was solved using MR with the WT Mps1 coordinates as a search model. The final model included residues Glu516 -Met671, Asp681 -Met698 and Ile711 -Thr795. The R factor and R free are 0.223/ 0.289, and 0.221 / 0.261 for the final WT-apo and T686A-SP600125 models, respectively (Table I ). All diffraction data were integrated and scaled using Mosflm (17) and Scala (18) , respectively. Crystallographic refinement and model fitting were done using Refmac5 (19) and Coot (20) . Figures were prepared with PyMol (21). Atomic coordinates and structure factors have been deposited in the PDB under accession ID's: 2ZMC (WT apo-Mps1) and 2ZMD (T686A-SP600125 Mps1 complex).
Enzyme assays and Western blotting. Purified Mps1 (500 ng) was added to a reaction mixture containing 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.1 mM EGTA, 10 mM MgCl 2 , 0.1% β-mercaptoethanol, 100 µM [γ-32 P]ATP (~500 cpm/pmole) and assayed using 20 µg of the exogenous substrate myelin basic protein (MBP, Upstate) for 30 min at 30°C. Phosphate incorporation was assessed by autoradiography after SDS-PAGE. Purified WT Mps1 (2 µg) was incubated with 400 U of λ-phosphatase and 2 mM MnCl 2 at 30°C. After 60 min, λ-phosphatase was inactivated with 10 mM sodium orthovanadate and the reaction mixture was subjected to kinase assay and Western blotting. Mps1 was immunoblotted with either antiphosphotyrosine antibody (Upstate), or antiMps1 C-terminal antibody (Upstate).
Results and discussion
Biochemical analysis of Mps1 catalytic domain. The C-terminal catalytic domain of Mps1, as expressed in bacteria, was assayed for enzymatic activity to validate the native state of the recombinant protein. The affinitypurified Mps1 catalytic domain was active towards the exogenous substrate MBP (Fig.  1A ). This suggests that the N-terminal region of Mps1 is not required for enzyme activity, in line with its reported role as a targeting domain (22) . To investigate the molecular basis of Mps1 activity, we mutated the DFG loop residue Asp664 to Ala, which completely abolished enzyme activity (Fig. 1A) . Another conserved residue, Thr686, located in the P+1 loop region (C-terminal to the activation loop) has recently been demonstrated to be autophosphorylated in vitro (8) . Mutation of Thr686 to Ala also resulted in a catalytically disabled mutant with no kinase activity (Fig.  1A ). This suggests that Thr686 is important for catalytic function, and that autophosphorylation of this site may therefore regulate Mps1 activity. The Mps1 catalytic domain was sensitive to the inhibitor SP600125 (Fig. 1A) , as previously shown for endogenous Mps1 immunoprecipitated from human cells (13) . Next, we analysed the effect of dephosphorylation on the activity of partially purified and electrophoretically pure WT Mps1 catalytic domains (Fig. 1B) . We found that Mps1 assayed after gel filtration was phosphorylated on tyrosine residues and active towards MBP (Fig. 1B, lane 1) . Subsequently, we dephosphorylated Mps1 with λ-phosphatase, and demonstrated that this led to the loss of phosphotyrosine antibody reactivity. Interestingly however, we were unable to demonstrate enzyme inactivation upon dephosphorylation, because addition of [γ-32 P]ATP rapidly led to re-phosphorylation of the Mps1 (as evidenced by increased 32 Pincorporation) and enzymatic activity towards MBP (Fig. 1B, Lane 2) . Dephosphorylated Mps1 was further purified on Mono Q, and this dephosphorylated protein was subsequently used for crystallographic trials. This preparation could also reactivate in the presence of ATP (Fig. 1B, Lane 3) .
Overall structure of Mps1. We have determined the crystal structures of the nonphosphorylated Mps1 catalytic domain apoenzyme, and a complex of the T686A mutant with SP600125. Mps1 exhibits a characteristic bilobal kinase fold, with a small N-terminal lobe (residues Glu516 -Met602) containing six β-strands and a 20-residues long α-helix (αC), and a large C-terminal lobe (residues Asn606-Gln794) consisting mostly of helices ( Fig. 2A) . The two lobes are connected by a hinge loop (residues Glu603 -Gly605) at the back of the active site cleft. The activation loop is only partially visible, with residues Gln672 to Lys680 poorly defined in the electron density maps and therefore omitted during refinement. Likewise, residues Ser699-Lys708 were not included in the final structure.
The overall architecture of Mps1 is very similar to that of phosphorylase kinase (Phk) (23) , with a C α root mean square deviation (r.m.s.d.) of 2.74 Å when 234 C α atoms were aligned, despite the low sequence homology of 28% in the catalytic domain. An important difference between the structures is the conformation of the activation loop. Phk is a constitutively active kinase that does not require phosphorylation at the activation loop to generate full catalytic activity, whereas phosphorylation of the activation segment in Mps1 is important for enzyme activity (8, 9) . In the Phk structure, the activation loop is extended over the C-terminal lobe, and anchored by electrostatic interactions with the catalytic loop involving the "RD motif" (23) , comparable to the active conformation of phosphorylated cAPK (24) . This extended conformation allows full access to the ATPbinding site in the active site cleft and creates a substrate-binding interface at the C-terminal (P+1) region of the activation loop.
In contrast, the activation loop in Mps1 bends back to the N-terminal lobe, partially occluding the active site cleft opening, disrupting the N-terminal anchor of the activation loop and displacing the αC helix (Fig. 2B) . As a consequence of this displacement, Glu571 in αC is unable to form ionic interactions with Lys553 (Fig. 2B) . The orientation of this conserved lysine residue is important for proper alignment of the ATP phosphates in productive catalysis and transfer of the γ-phosphate to the substrate (23, 24) . This orientation is maintained by an ionic interaction with the conserved glutamic acid residue in the αC helix. The displacement of αC in the structure of the unphosphorylated Mps1, and subsequent disengagement of this ion pair, suggests that the orientation of Lys553 is not optimal for catalysis. Displacement of the αC helix due to steric hindrance by the activation loop has been described for other kinases of the Src kinase family (25) and recognised as an important mechanism for regulating enzyme activity (26) . A similar structural flexibility was observed for Aurora A, a mitotic kinase that is also regulated by autophosphorylation (27) . The structure of unphosphorylated Aurora A in complex with adenosine shows an identical disengagement of the Lys=Glu interaction, driven by hindrance from the activation loop (28) . In contrast, the structure of phosphorylated Aurora A (29), exhibits a conformational change in the activation loop, which appears more extended towards the Cterminal lobe resulting in the re-alignment of αC and positioning of Glu181 in closer contact with Lys162 (Fig. 2B) .
We predict that a comparable regulatory mechanism is likely to apply to Mps1, where phosphorylation at the activation loop may drive conformational changes that release the steric hindrance of αC, restoring Lys553 interaction with Glu571. This is supported in part by our biochemical data, which demonstrate that the inactive state of Mps,1 as observed in the crystal structure, can be reversed by the addition of ATP in vitro, which induces autophosphorylation and recovery of catalytic activity (Fig. 1B) . A high-resolution structure of active phosphorylated Mps1 is needed to corroborate this model. Structural comparison with other kinases shows that except for Lys553, the remainder of the conserved catalytic residues are correctly oriented in unphosphorylated Mps1. These include Asp646 in the catalytic loop, which is involved in phosphate transfer to the substrate, and Asp664 in the DFG-loop, which coordinates the magnesium ion for ATP hydrolysis. Another important implication of the activation loop conformation in unphosphorylated Mps1 is the lack of electrostatic interactions between the catalytic loop and the P+1-loop, where the functionally important Thr686 residue is located. The effect of mutation at Thr686 is not clear, since mutation to Asp to mimic phosphorylation, does not rescue the activity of budding yeast Mps1 (8) , or human Mps1 (Tyler et al., submitted for publication). Although this residue is well defined in the density maps of the apo-kinase structure, there are no obvious interactions with the catalytic loop, as found in other active kinases, or with other regions of the kinase domain. The structure of the T686A mutant has an almost identical conformation at the P+1-loop as the WT structure (Fig. 2C) . One possible explanation is that upon phosphorylation, conformational changes in the activation loop could bring this residue in closer contact to the catalytic loop for interaction. Phosphorylation of Thr686 may be required to mediate such interactions, as observed for the phosphorylated activation loop residue in many kinases (26) . Alignment of the P+1-loop with the catalytic loop is important in forming the substrate-binding interface, and is critical for kinase activity in Ser/Thr kinases (26) . The essential role of Thr686 for catalytic activity (Fig. 1A) could therefore reflect a contribution to substrate binding.
Complex of Mps1 with SP600125
SP600125 is an ATP-competitive kinase inhibitor, which was originally described as an inhibitor of JNK1, 2 and 3 (10). It has also been valuable to validate the cellular functions of Mps1, with which JNK isoforms share some conserved features in the ATP-binding site (5, 13) . We observed that inhibition of the purified Mps1 catalytic domain was > 90 % complete in the presence of 10 µM SP600125 (Fig. 1A) . To determine the mode of binding of this compound we solved the structure of the T686A-SP600215 complex. The structures of both WT Mps1 apo-kinase and T686A-SP600125 exhibit only minor differences when superimposed, with an overall C α r.m.s.d. of only 0.44 Å when 258 C α atoms were aligned. The difference electron density map clearly showed SP600125 bound in the adenine-binding pocket, at the interface between the N and C-terminal lobes (Fig. 3A) . The binding site is lined with non-aromatic hydrophobic residues, including Ile531, Val539, Ala551 at the top and Ile586, Ile663 and Leu654 at the bottom, which sandwich the inhibitor (Fig. 3A) . Binding is further strengthened by hydrogen bonds between SP600215 N1 and Gly605 main-chain NH, and SP600125 N2 and Glu603 main-chain carbonyl oxygen (Fig. 3A) . This binding mode is similar to the observed in the JNK1-SP600125 complex, including van der Waals contacts with Met602. This methionine is conserved in JNK1-3, PKB and PKA but not in several other kinases sensitive to inhibition by SP600125 (11) , and the importance of Met602 for inhibition of Mps1 activity has already been demonstrated by mutagenesis of this residue (13) .
By comparing the Mps1 and JNK1 inhibitor-binding sites, we observed several differences that could be exploited for structure-based drug design to aid the development of Mps1-specific compounds. Of particular interest is the replacement of the hydrophobic Leu110 in JNK1 by Cys604 in Mps1. This represents a possible target for polar or disulfide interactions by inhibitor molecules. In addition, differences between the position of Ile663 side chain in Mps1 and that of Leu168 in JNK1, generate a cavity at the bottom floor of the hydrophobic pocket, which might specifically accommodate alternative groups at the carbonyl oxygen position of the inhibitor (Fig. 3B) . Interestingly, as an extension of the ATP-binding site, we also identified a secondary pocket, at the internal face of αC. This pocket is made available in the unphosphorylated form of Mps1 because of the disruption of the Glu571=Lys553 ion pair, but not in JNK1, where this interaction is maintained. The smaller size of the secondary pocket in JNK1 is also explained by the position of Met77 and Ile106 side chains that form a gate, occluding the pocket (Fig. 3B) . In Mps1, this pocket contains two tyrosine residues, Tyr568 and Tyr591, which could be targeted for π−stacking interactions with inhibitors to improve specificity. The secondary pocket accommodates a molecule of PEG from the crystallisation solution, where it wraps around Lys553 in an orientation that promotes electrostatic interactions with its ether oxygens (Fig. 3C) . Our finding that this secondary pocket is present in the unphosphorylated form of the kinase, suggests that inhibitors developed to interact in this region could be used to target inactive Mps1. This might provide a selective advantage for the mechanism of inhibition by a small molecule. A similar strategy has proved especially important in the development of therapeutic inhibitors such as Imatinib, which bind with high affinity to an unphosphorylated, inactive species of the tyrosine kinase BCR-ABL (30) .
In summary, we present the first crystallographic structure of human Mps1, an important regulator of chromosomal stability and a potential target in cancer therapy. The unphosphorylated form of the kinase domain shows a closed activation loop conformation, which causes long-range alterations of the catalytic lysine residue, thus suggesting a potential mechanism of Mps1 activation by phosphorylation. A complex with the ATPcompetitive inhibitor SP600125 reveals several important structural features and additional binding sites that could be exploited for the development of specific Mps1 inhibitors. 
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